RE:RE:RE:ONCY’s Phase 1b/2 mPC results compared over 2019 to 2023** CORRECTION** :
Side x Side comparision of pelareorep + ATEZOLIZUMAB (TECENTRIQ) + nab-Paclitaxel plus Gemcitabine interim results versus control Von Hoff, et al results of nab-Paclitaxel plus Gemcitabine -> Von Hoff, et al., NEJM 2013 - Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430).
The median overall survival was 8.5 months in the nab-paclitaxel–gemcitabine group as compared with 6.7 months in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). The survival rate was 35% in the nab-paclitaxel–gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was 5.5 months in the nab-paclitaxel–gemcitabine group, as compared with 3.7 months in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% versus 7% in the two groups (P<0.001). Versus GOBLET Phase 1/2 metastatic pancreatic cancer results -> On October 16, 2023 the GOBLET Phase 1/2 metastatic pancreatic cancer abstract was released at ESMO and reported on results in patients who were treated with pelareorep + atezolizumab + chemotherapy (nab-paclitaxel). Preliminary results were updated PDAC data showing a median PFS of 7.2 months, interim median overall survival of 10.6 months, expansion of both pre-existing and new T-cell clones and a 6-month survival rate of 82% in a patient population comprised of patients where 92% presented with metastatic disease, 69% in the liver - the worst of the worst - which historically only 10% survive longer than one (1) year.
The results showed that 8 of 13 evaluable patients had a partial response (PR) in a patient population which historically have not responded to in the past. A partial response (PR) is defined as at least a 30% decrease in the sum of the target lesions.